What Baxter Biopharma Solutions does

Simtra BioPharma Solutions (formerly Baxter Biopharma Solutions) is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals. Founded in 1931 and headquartered in Bloomington, Indiana, the company operates two cGMP-compliant, ISO 14001-certified manufacturing campuses — Bloomington, Indiana (USA) and Halle/Westfalen (Germany) — and distributes manufactured products to patients in more than 120 countries. Its service portfolio spans formulation development, lyophilization cycle development and optimization, rapid technology transfer, fill/finish operations, specialized containment for cytotoxics and highly potent compounds, analytical services, and global regulatory support, with delivery formats including liquid vials, lyophilized vials, and prefilled syringes across drug categories ranging from small molecules to biologics, vaccines, and diluents.

The company's underlying technology platform is built around sterile injectable manufacturing — encompassing aseptic fill/finish, lyophilization, and specialized containment — and is being extended upstream into bioconjugation to deliver integrated drug-substance-to-drug-product solutions, particularly for antibody drug conjugates (ADCs). Capital infrastructure is a defining feature: a recent strategic purchase from Cook Group added a 65-acre property with more than 300,000 square feet of available expansion space adjacent to the Bloomington site, and a new production building has been completed at the German campus. A five-year strategic alliance with MilliporeSigma (the Life Science business of Merck KGaA) combines Simtra's fill/finish expertise with bioconjugation and antibody capabilities to offer an end-to-end ADC manufacturing ecosystem.

Simtra generates revenue through fee-for-service contract manufacturing for pharmaceutical and biotech clients across clinical and commercial stages, supplemented by long-term managed-service commercial supply agreements that produce recurring revenue. Pricing is not publicly disclosed and is negotiated project-by-project based on molecule complexity, batch size, regulatory pathway, and service scope. The go-to-market motion is consultative and enterprise-focused, engaging directly with pharma and biotech decision-makers (VP Manufacturing, CTO-level) through relationship-driven sales cycles, supported by content marketing, industry events, earned media, and LinkedIn presence. The company serves a horizontal segmentation of pharmaceutical and biotech customers, with ADC developers as a strategically emphasized secondary segment. Following its separation from Baxter International, the company now operates as an independent private CDMO under the Simtra brand.

Name

Baxter Biopharma Solutions

Legal name

Baxter BioPharma Solutions

Website

https://baxterbiopharmasolutions.com

Company type

Private

Founded year

1931

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Sterile Injectable CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Sterile injectable manufacturing
• Contract development manufacturing
• Aseptic fill finish
• Lyophilization cycle development
• Bioconjugation ADC services

Headquarters

HQ city

Bloomington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Simtra operates as a CDMO providing fee-for-service contract manufacturing to pharmaceutical and biotech companies. Revenue is generated through service contracts for formulation development, fill/finish operations, lyophilization, analytical services, and technology transfer across clinical and commercial stages. The business model is project-based and relationship-driven, consistent with the CDMO/CMO industry standard.
2. Commercial Manufacturing Supply: Long-term supply agreements for commercial-stage sterile injectable products, providing recurring revenue from manufacturing scale-up and ongoing production for approved drugs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Baxter Biopharma Solutions (now operating as Simtra BioPharma Solutions) is a contract development and manufacturing organization (CDMO) providing formulation development, lyophilization cycle development, rapid technology transfer, fill/finish operations, specialized containment for potent compounds, analytical services, and global regulatory support for sterile injectable pharmaceuticals. The company manufactures across cytotoxics, highly potent compounds, biologics, vaccines, small molecules, and diluents in liquid vials, lyophilized vials, and prefilled syringes from cGMP-compliant facilities in Bloomington, Indiana (USA) and Halle/Westfalen, Germany, with products distributed to patients in 120+ countries.

Product overview

Based on the source data, Baxter Biopharma Solutions is mentioned as a participant in fill-finish partnership announcements within the aseptic fill finish market. The company operates in the pharmaceutical contract manufacturing space, specifically in aseptic fill finish services for biologics and vaccines. No detailed product portfolio, modules, or service offerings were extracted from the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation Development

Quantifiable outcome

• Products distributed in 120+ countries
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• MilliporeSigma (Life Science business of Merck KGaA, Darmstadt, Germany)coreStrategic or Co-development Partner · 1 October 2025Simtra BioPharma Solutions and MilliporeSigma announced a five-year strategic alliance for antibody drug conjugate (ADC) drug substance and drug product manufacturing services. The alliance enables an integrated ADC offering, combining Simtra's sterile injectable fill/finish expertise with MilliporeSigma's bioconjugation and antibody manufacturing capabilities. The partnership creates an end-to-end solution for ADC development and manufacturing under one ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Recipharm: European-headquartered CDMO offering sterile injectable fill-finish and other pharmaceutical manufacturing services. Directly comparable on sterile fill-finish capabilities, though with a stronger small-molecule/specialty focus than Simtra.
• Lonza: One of the world's largest CDMOs offering sterile injectable, biologics, and small-molecule manufacturing. Comparable on end-to-end development-to-commercial services, cGMP infrastructure, and global multi-site footprint serving pharma customers.
• Aenova Group: European pharmaceutical CDMO with sterile manufacturing, including lyophilization and prefilled syringe capabilities. Comparable on sterile fill-finish service offerings and customer base of mid-to-large pharma.
• Catalent: Global CDMO leader with large-scale sterile injectable fill-finish and biologics manufacturing capabilities, serving many of the same pharmaceutical and biotech customers as Simtra across clinical and commercial stages. Most directly comparable on sterile fill-finish scope and customer base.
• WuXi STA (WuXi AppTec): Major global CDMO with significant sterile injectable and biologics manufacturing capacity. Comparable on large-scale aseptic fill-finish for innovative pharma, though with a distinct geographic and customer mix.
• Thermo Fisher Scientific (Patheon): Through its Patheon pharma services business, Thermo Fisher offers sterile injectable fill-finish and broader CDMO services globally. Directly comparable in serving large pharma customers with sterile fill-finish, formulation, and analytical services.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's biopharmaceutical contract manufacturing business, focused on biologics fill-finish, including for highly potent compounds. Directly comparable on mammalian-based biologics fill/finish and process complexity.

Broad incumbents

• Samsung Biologics: Large-scale biologics contract manufacturer offering drug substance and aseptic fill-finish services. Comparable as a high-capacity, fully integrated biologics CDMO, though primarily Asian-headquartered and with a biologics-skewed portfolio.
• Pfizer CentreOne: Pfizer's contract manufacturing arm offering sterile injectable and API manufacturing services to external customers. Comparable on sterile injectable capabilities and access to large-pharma-grade cGMP infrastructure.

Others

• MilliporeSigma: Life Science business of Merck KGaA providing bioconjugation, antibody manufacturing, and ADC development services. Connected to Simtra via a five-year strategic alliance, and complementary (rather than directly competitive) on the ADC value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baxter Biopharma Solutions